Illumina, Inc. (0J8Z.L)
USD 70.61
(-3.17%)
USD 70.61
(-3.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.11 Billion USD | -17.47% |
| 2022 | 12.25 Billion USD | -19.48% |
| 2021 | 15.21 Billion USD | 100.62% |
| 2020 | 7.58 Billion USD | 3.68% |
| 2019 | 7.31 Billion USD | 5.13% |
| 2018 | 6.95 Billion USD | 32.38% |
| 2017 | 5.25 Billion USD | 22.81% |
| 2016 | 4.28 Billion USD | 16.08% |
| 2015 | 3.68 Billion USD | 10.5% |
| 2014 | 3.33 Billion USD | 10.55% |
| 2013 | 3.01 Billion USD | 17.65% |
| 2012 | 2.56 Billion USD | 16.86% |
| 2011 | 2.19 Billion USD | 19.4% |
| 2010 | 1.83 Billion USD | 28.61% |
| 2009 | 1.42 Billion USD | 3.84% |
| 2008 | 1.37 Billion USD | 39.42% |
| 2007 | 987.73 Million USD | 228.6% |
| 2006 | 300.58 Million USD | 198.76% |
| 2005 | 100.61 Million USD | 6.01% |
| 2004 | 94.9 Million USD | -4.36% |
| 2003 | 99.23 Million USD | -18.6% |
| 2002 | 121.9 Million USD | -0.46% |
| 2001 | 122.46 Million USD | -7.78% |
| 2000 | 132.79 Million USD | 291.78% |
| 1999 | 33.89 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.04 Billion USD | -0.7% |
| 2024 Q3 | 6.01 Billion USD | -1.1% |
| 2024 Q2 | 6.08 Billion USD | -39.43% |
| 2023 Q4 | 10.11 Billion USD | -0.11% |
| 2023 Q3 | 10.12 Billion USD | -14.03% |
| 2023 FY | 10.11 Billion USD | -17.47% |
| 2023 Q1 | 11.81 Billion USD | -3.6% |
| 2023 Q2 | 11.77 Billion USD | -0.31% |
| 2022 Q3 | 11.25 Billion USD | -27.14% |
| 2022 Q4 | 12.25 Billion USD | 8.85% |
| 2022 FY | 12.25 Billion USD | -19.48% |
| 2022 Q1 | 15.27 Billion USD | 0.37% |
| 2022 Q2 | 15.44 Billion USD | 1.14% |
| 2021 Q2 | 8.67 Billion USD | -0.91% |
| 2021 FY | 15.21 Billion USD | 100.62% |
| 2021 Q1 | 8.75 Billion USD | 15.43% |
| 2021 Q4 | 15.21 Billion USD | 1.02% |
| 2021 Q3 | 15.06 Billion USD | 73.64% |
| 2020 FY | 7.58 Billion USD | 3.68% |
| 2020 Q1 | 7.26 Billion USD | -0.75% |
| 2020 Q2 | 7.24 Billion USD | -0.18% |
| 2020 Q4 | 7.58 Billion USD | 2.44% |
| 2020 Q3 | 7.4 Billion USD | 2.15% |
| 2019 Q4 | 7.31 Billion USD | 3.2% |
| 2019 FY | 7.31 Billion USD | 5.13% |
| 2019 Q3 | 7.08 Billion USD | 1.66% |
| 2019 Q1 | 7.39 Billion USD | 6.19% |
| 2019 Q2 | 6.97 Billion USD | -5.64% |
| 2018 FY | 6.95 Billion USD | 32.38% |
| 2018 Q1 | 5.54 Billion USD | 5.42% |
| 2018 Q2 | 5.85 Billion USD | 5.58% |
| 2018 Q3 | 6.75 Billion USD | 15.52% |
| 2018 Q4 | 6.95 Billion USD | 2.96% |
| 2017 Q1 | 4.59 Billion USD | 7.41% |
| 2017 Q4 | 5.25 Billion USD | 4.18% |
| 2017 Q3 | 5.04 Billion USD | 3.87% |
| 2017 Q2 | 4.85 Billion USD | 5.65% |
| 2017 FY | 5.25 Billion USD | 22.81% |
| 2016 FY | 4.28 Billion USD | 16.08% |
| 2016 Q4 | 4.28 Billion USD | 1.25% |
| 2016 Q3 | 4.22 Billion USD | 6.09% |
| 2016 Q2 | 3.98 Billion USD | 5.04% |
| 2016 Q1 | 3.79 Billion USD | 2.87% |
| 2015 Q1 | 3.49 Billion USD | 4.84% |
| 2015 FY | 3.68 Billion USD | 10.5% |
| 2015 Q2 | 3.7 Billion USD | 5.83% |
| 2015 Q4 | 3.68 Billion USD | -1.23% |
| 2015 Q3 | 3.73 Billion USD | 0.82% |
| 2014 Q3 | 3.27 Billion USD | 8.01% |
| 2014 FY | 3.33 Billion USD | 10.55% |
| 2014 Q4 | 3.33 Billion USD | 1.81% |
| 2014 Q2 | 3.03 Billion USD | -0.61% |
| 2014 Q1 | 3.05 Billion USD | 1.14% |
| 2013 FY | 3.01 Billion USD | 17.65% |
| 2013 Q4 | 3.01 Billion USD | 7.14% |
| 2013 Q1 | 2.74 Billion USD | 6.94% |
| 2013 Q2 | 2.82 Billion USD | 2.88% |
| 2013 Q3 | 2.81 Billion USD | -0.2% |
| 2012 FY | 2.56 Billion USD | 16.86% |
| 2012 Q1 | 2.3 Billion USD | 4.81% |
| 2012 Q3 | 2.43 Billion USD | 3.8% |
| 2012 Q4 | 2.56 Billion USD | 5.25% |
| 2012 Q2 | 2.34 Billion USD | 2.05% |
| 2011 Q3 | 2.14 Billion USD | -4.87% |
| 2011 FY | 2.19 Billion USD | 19.4% |
| 2011 Q4 | 2.19 Billion USD | 2.27% |
| 2011 Q2 | 2.25 Billion USD | 6.3% |
| 2011 Q1 | 2.12 Billion USD | 15.44% |
| 2010 Q4 | 1.83 Billion USD | 6.6% |
| 2010 FY | 1.83 Billion USD | 28.61% |
| 2010 Q3 | 1.72 Billion USD | 5.08% |
| 2010 Q1 | 1.5 Billion USD | 5.26% |
| 2010 Q2 | 1.64 Billion USD | 9.08% |
| 2009 Q4 | 1.42 Billion USD | -7.25% |
| 2009 FY | 1.42 Billion USD | 3.84% |
| 2009 Q1 | 1.37 Billion USD | -0.33% |
| 2009 Q2 | 1.47 Billion USD | 7.62% |
| 2009 Q3 | 1.54 Billion USD | 4.37% |
| 2008 Q1 | 935.75 Million USD | -5.26% |
| 2008 Q3 | 1.36 Billion USD | 37.14% |
| 2008 Q4 | 1.37 Billion USD | 1.16% |
| 2008 FY | 1.37 Billion USD | 39.42% |
| 2008 Q2 | 992.68 Million USD | 6.08% |
| 2007 Q3 | 810.2 Million USD | 4.74% |
| 2007 Q1 | 742.83 Million USD | 147.13% |
| 2007 FY | 987.73 Million USD | 228.6% |
| 2007 Q2 | 773.57 Million USD | 4.14% |
| 2007 Q4 | 987.73 Million USD | 21.91% |
| 2006 FY | 300.58 Million USD | 198.76% |
| 2006 Q2 | 230.95 Million USD | 105.24% |
| 2006 Q1 | 112.52 Million USD | 11.84% |
| 2006 Q3 | 256.47 Million USD | 11.05% |
| 2006 Q4 | 300.58 Million USD | 17.2% |
| 2005 Q2 | 91.25 Million USD | -2.69% |
| 2005 FY | 100.61 Million USD | 6.01% |
| 2005 Q4 | 100.61 Million USD | 3.69% |
| 2005 Q3 | 97.02 Million USD | 6.32% |
| 2005 Q1 | 93.78 Million USD | -1.19% |
| 2004 FY | 94.9 Million USD | -4.36% |
| 2004 Q3 | 92.07 Million USD | -26.52% |
| 2004 Q2 | 125.3 Million USD | 27.57% |
| 2004 Q4 | 94.9 Million USD | 3.08% |
| 2004 Q1 | 98.22 Million USD | -1.02% |
| 2003 Q3 | 106.27 Million USD | -0.24% |
| 2003 Q4 | 99.23 Million USD | -6.63% |
| 2003 FY | 99.23 Million USD | -18.6% |
| 2003 Q1 | 115.21 Million USD | -5.49% |
| 2003 Q2 | 106.53 Million USD | -7.54% |
| 2002 FY | 121.9 Million USD | -0.46% |
| 2002 Q1 | 140.55 Million USD | 14.77% |
| 2002 Q2 | 133.61 Million USD | -4.94% |
| 2002 Q3 | 128.46 Million USD | -3.85% |
| 2002 Q4 | 121.9 Million USD | -5.11% |
| 2001 Q1 | 130.69 Million USD | -1.58% |
| 2001 Q2 | 130.15 Million USD | -0.41% |
| 2001 Q4 | 122.46 Million USD | -3.98% |
| 2001 Q3 | 127.54 Million USD | -2.0% |
| 2001 FY | 122.46 Million USD | -7.78% |
| 2000 Q2 | 33.69 Million USD | -2.14% |
| 2000 Q4 | 132.79 Million USD | -1.61% |
| 2000 Q1 | 34.43 Million USD | 0.0% |
| 2000 Q3 | 134.96 Million USD | 300.56% |
| 2000 FY | 132.79 Million USD | 291.78% |
| 1999 FY | 33.89 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -1115.719% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -978.946% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -1199.815% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -6009.218% |
| bluebird bio, Inc. | 619.16 Million USD | -1533.016% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -7934.551% |
| Imunon, Inc. | 21.91 Million USD | -46030.889% |
| Editas Medicine, Inc. | 499.15 Million USD | -1925.631% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 62.104% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -201.321% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -743.497% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -210.974% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -617.613% |
| Verastem, Inc. | 149.71 Million USD | -6653.363% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 87.523% |
| Waters Corporation | 4.62 Billion USD | -118.529% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 89.759% |
| Biogen Inc. | 26.84 Billion USD | 62.335% |
| Nektar Therapeutics | 398.03 Million USD | -2440.242% |
| Perrigo Company plc | 10.8 Billion USD | 6.458% |
| Dynavax Technologies Corporation | 997.09 Million USD | -914.045% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -35662.802% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -1195.699% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -4444.147% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -15291.993% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -47.787% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -6016.017% |
| Evolus, Inc. | 188.99 Million USD | -5249.792% |
| Adicet Bio, Inc. | 207.29 Million USD | -4777.59% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -5021.957% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 69.435% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -4813.118% |
| FibroGen, Inc. | 423.52 Million USD | -2287.322% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 6.058% |
| OPKO Health, Inc. | 2.01 Billion USD | -402.61% |
| Homology Medicines, Inc. | 47.05 Million USD | -21386.708% |
| Geron Corporation | 394.07 Million USD | -2465.749% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -164.003% |
| Exelixis, Inc. | 2.94 Billion USD | -243.636% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -2643.901% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -6449.169% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -677.185% |
| Zoetis Inc. | 14.28 Billion USD | 29.224% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1618.868% |
| Abeona Therapeutics Inc. | 64 Million USD | -15697.944% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 55.517% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -17971.815% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -238.152% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -209.719% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -1526.826% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -483.348% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -863.641% |
| Insmed Incorporated | 1.32 Billion USD | -660.319% |
| TG Therapeutics, Inc. | 329.58 Million USD | -2967.779% |
| Incyte Corporation | 6.78 Billion USD | -49.083% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -451.038% |